These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18662494)

  • 1. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang HL; Vaidyanathan S; Yeh CM; Bizot MN; Dieterich HA; Dole WP; Howard D
    Curr Med Res Opin; 2008 Sep; 24(9):2449-56. PubMed ID: 18662494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
    Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
    Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
    Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
    Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
    Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
    Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
    Dieterle W; Corynen S; Mann J
    Br J Clin Pharmacol; 2004 Oct; 58(4):433-6. PubMed ID: 15373937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
    Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
    Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
    Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
    Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
    Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
    Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
    J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol.
    Rolan P; Terpstra IJ; Clarke C; Mullins F; Visser JN
    Br J Clin Pharmacol; 2003 Mar; 55(3):314-6. PubMed ID: 12630984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics.
    de Hoon JN; Thijssen HH; Beysens AJ; Van Bortel LM
    Br J Clin Pharmacol; 1997 Oct; 44(4):399-401. PubMed ID: 9354316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
    Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
    Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
    Khadzhynov D; Slowinski T; Lieker I; Neumayer HH; Albrecht D; Streefkerk HJ; Rebello S; Peters H
    Clin Pharmacokinet; 2012 Oct; 51(10):661-9. PubMed ID: 23018529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
    Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
    Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
    Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
    Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
    J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.